Class III antiarrhythmics |
|
|
-
Efficacy at 1 y 60%-70% (most effective) -
CTAF trial18 showed amiodarone was more efficacious at preventing AF than propafenone or sotalol were -
Possesses both rate- and rhythm-control mechanisms -
Can be used in patients with renal dysfunction or HF (LVEF ≤ 35%)
|
-
Safety: many serious side effects that require judicious monitoring (see Table 7) -
Considerable drug interactions (especially with warfarin; must decrease warfarin dose) -
Loading dose and extensive titrating schedule required -
Long half-life (26-107 d)
|
|
|
|
|
-
Should NOT be used in patients with permanent AF (increased CV mortality) -
Relatively new drug; limited experience with efficacy and safety -
Not covered by provincial formularies (not recommended by CDR)19
|
|
|
|
-
Possesses proarrhythmic qualities -
CI in patients with CrCl < 40 mL/min (renally eliminated) -
Bradycardia common in elderly patients -
Avoid in women > 65 y who are taking diuretics or who have renal impairment owing to increased risk of torsade de pointes
|
|
Class I antiarrhythmics |
|
|
|
-
Should be coupled with an AV nodal blocking agent (β-blocker or CCB) owing to concealed conduction and risk of ventricular tachycardia -
CI in structural heart disease -
Can have serious cardiac side effects (cardiac arrest, arrhythmia, AV node block)
|
|
|
| |
|
|